Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications

Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications

Meningiomas account for approximately 30% of all new diagnoses of intracranial masses. The 2016 World Health Organization’s (WHO) classification currently represents the clinical standard for meningioma’s grading and prognostic stratification. However, watchful waiting is frequen...

Full description

Bibliographic Details
Main Authors: Riccardo Laudicella, Domenico Albano, Salvatore Annunziata, Diletta Calabrò, Giovanni Argiroffi, Elisabetta Abenavoli, Flavia Linguanti, Antonio Vento, Antonio Bruno, Pierpaolo Alongi, Matteo Bauckneht
Format: Article
Language:English
Published: MDPI AG 2019-09-01
Series:Cancers
Subjects:
meningioma
somatostatin receptor
neuroimaging
positron emission tomography
radionuclide therapy
Online Access:https://www.mdpi.com/2072-6694/11/10/1412

Internet

https://www.mdpi.com/2072-6694/11/10/1412

Similar Items